Women & Cannabis: The Gender Reversal in 2026 Consumption Trends

Here is a statistic that, when I first encountered it, required a second read.

In 2023, women aged 19 to 30 surpassed men of the same age in cannabis consumption — for the first time in the nearly 50-year history of the Monitoring the Future study, which has tracked substance use across American society since 1976. That is not a rounding error or a regional blip. It is a documented inflection in data that stretches back to before most of today’s cannabis consumers were born.

For half a century, men used cannabis at roughly double the rate of women. The gender gap was one of the most stable demographic constants in drug use research — more predictable, some analysts noted, than income or education as a predictor of cannabis use. And then, over the better part of a decade, it began to close. And in certain segments, it has reversed entirely.

What happened? The data has a clear answer. The social science is still catching up.

The Historical Pattern

Go back to the early 2000s and the picture is unambiguous. According to the 2019 National Survey on Drug Use and Health — before the most recent trend acceleration — 20.4% of men aged 12 and older reported past-year cannabis use compared with 14.8% of women. That ~6-point gap had been the norm, give or take, for decades.

The gap was not just about frequency. It was about culture. The archetypal cannabis consumer in mainstream American imagery — from stoner comedies to drug war propaganda posters — was male. The product experience was designed around that consumer: high-THC flower, concentrate potency contests, blunt culture. The dispensary “bro” was not a caricature invented by the industry’s critics. He was the target market.

Then legalization changed the math.

A landmark study published in PLOS ONE examining data from 2008 to 2017 found that recreational cannabis legalization was associated with higher increases in both past-year and past-month cannabis use among women (+3.2% and +2.3% respectively) compared with men (+2.1% and +1.7%). The legal market did not just expand the consumer base — it expanded it asymmetrically, with women showing faster uptake. The researchers described this as legalization “contributing to the narrowing of the cannabis gender gap.”

The gap has not just narrowed. In key segments, it has closed or flipped.

The Reversal — Where It Is Showing Up First

The clearest reversal is in young adults. Women aged 19 to 30 now report higher past-year cannabis use than men in the same cohort — the headline data point from the 2023 Monitoring the Future panel, which has been running since 1976 and carries substantial methodological weight.

Among adolescents, the shift is even more pronounced. A 2026 study published in Drug and Alcohol Dependence found that in 2022, adolescent females surpassed males in past-month cannabis use (a 2.3 percentage point difference). By 2023, female adolescents showed significantly higher rates of both daily/near-daily use and cannabis use disorder prevalence than their male counterparts. Lifetime use data shows a similar inversion: in 2023, female adolescents reported 33.4% lifetime use versus 27.0% for males.

Among adult women overall, the picture is more nuanced. Women still account for approximately 42% of cannabis consumers in 2025, up from 35% in 2020 — the fastest-growing demographic segment in the market. At the dispensary level, the shift is already felt: Women now make up 55% of the user base on Jointly, a cannabis discovery platform, and in September 2024, average purchase size for female buyers at Housing Works Cannabis Co. in New York exceeded that of male buyers ($91 vs. $89).

Women aged 35 and older still use cannabis at lower overall rates than men of the same age. But the trajectory in that cohort is moving in the same direction — particularly around specific use cases. Which brings us to what may be the most important part of the story: why women are using cannabis, and what they are choosing to buy.

Why Women Are Choosing What They Are Choosing

The Monitoring the Future researchers and others studying the gender shift consistently point to motivation as the key differentiating variable.

Studies published in the Journal of Psychology of Addictive Behaviors find that women are more likely than men to use cannabis for coping — specifically to manage stress, anxiety, negative emotions, and physical discomfort. Men, in the aggregate, are more likely to cite recreational motivation: using cannabis to get high, to enhance an already-good mood, or for social facilitation.

This is not a trivial distinction. It shapes everything downstream.

When you use cannabis to manage anxiety or pain, you want predictability. You want to know what you are getting. You want to avoid the outcomes — paranoia, rapid heartbeat, disorientation — that can accompany high doses of THC, particularly in infrequent users. And when you frame cannabis as a wellness tool rather than a recreational one, you are drawn to product categories that look and feel like wellness products.

Research consistently confirms this plays out in purchasing behavior. SAMHSA’s National Survey on Drug Use and Health (2022-2023 data) found that nearly 20% of male cannabis users cited smoking as their primary method — versus 14.3% of women. Women were roughly twice as likely as men to prefer topical products, and more inclined toward edibles and drinkable formats. New Frontier Data found that 29% of women prefer non-flower cannabis products, compared with just 15% of men.

YouGov data on female cannabis consumers confirms the pattern from a different angle: relaxation (70%) and sleep improvement (69%) top the list of reasons women use cannabis, followed by pain relief (53%) and anxiety or depression management (51%). Only 39% cited personal enjoyment in the traditional recreational sense.

Lower THC tolerance is a documented physiological reality, not a stereotype. Research in Cannabis and Cannabinoid Research and other peer-reviewed sources has found that females show greater sensitivity to the subjective effects of THC at equivalent doses — meaning that lower-dose products are not just a marketing preference for women, they may represent genuinely better calibration for a significant portion of female consumers.

For beginner consumers of any gender, this is worth knowing. Our beginner strain guide covers the principles of starting low and going slow — principles that align directly with what women are disproportionately choosing on their own. For a broader look at format tradeoffs, flower vs. edibles vs. concentrates is worth your time.

Terpene and Aroma Preferences

Here is where the data gets genuinely interesting, and where the industry has been slower to catch up.

A 2024 study published in Psychoactives tested the anxiolytic (anxiety-reducing) properties of two major cannabis terpenes — linalool and myrcene — in male and female subjects using vaporization protocols designed to mimic real cannabis use. The findings: both linalool and myrcene showed anxiolytic effects in female subjects when delivered in discrete vapor pulls over 30 minutes. In males, only a single vapor hit of linalool had anxiolytic effects. The researchers also found that the combination of sub-effective levels of linalool with CBD showed synergistic anxiolytic effects in females — effects not observed in males.

Put plainly: linalool may simply work better for anxiety in female consumers than in male consumers. And linalool is the dominant terpene in lavender — the floral, soft, calming end of the cannabis aroma spectrum.

This aligns with what dispensary data and consumer surveys report anecdotally: women show stronger preference for strains with citrus, floral, and herbal aroma profiles — the territory occupied by limonene (bright, citrus, uplifting) and linalool (lavender, calming). Male consumers, on average, skew heavier toward the earthy, diesel, and pungent profiles associated with caryophyllene and heavy myrcene expression.

This maps directly onto High Family preferences. The Uplift family — limonene-forward, bright, mood-lifting — and the Relax family — linalool and myrcene-dominant, tension-releasing — align well with the profiles women report preferring. The Balance family, with its CBD-forward formulations and measured THC ratios, also over-indexes in female consumer preference data.

Strains that exemplify the linalool-dominant profile include Do-Si-Dos, known for its soft floral-and-cookie character and gradual body calm, and Lavender Kush, one of the most linalool-forward cultivars in the mainstream market. Both sit squarely in the Relax family and are consistently cited by women consumers seeking tension relief without high-THC intensity.

None of this is deterministic. Individual variation exceeds group averages. But population-level terpene preference data is starting to be real and directional — and it matters for how you choose your next product.

The Wellness Branding Effect

The cannabis brands that have most successfully targeted female consumers share a few common traits: clean aesthetics, transparent dosing, wellness-first framing, and an absence of stoner-culture signifiers.

Beboe — the luxury cannabis brand founded by artist Scott Campbell, positioned as “the Hermès of cannabis” — built its identity around low-dose, precisely formulated products in sophisticated packaging designed to look at home on a nightstand, not a college dorm shelf. House of Wise built an entirely wellness-focused cannabis brand around women’s specific needs for sleep, sex, and stress. Kiva Confections, co-founded by Kristi Palmer, became one of the country’s most recognized edible brands by prioritizing consistent, precise dosing — exactly what the research shows female consumers prioritize.

These brands did not create the female consumer demand. They recognized it early and built for it.

The data from mg Magazine (March 2026) notes that women now represent more than half of all cannabis consumers according to Statista, and are “driving demand for wellness-forward categories like topicals, low-dose edibles, tinctures, and therapeutic formulations.” That is not a niche demographic signal. That is the center of gravity of the modern cannabis market.

Less than 3% of all cannabis financing goes to women-owned businesses — a figure cited by Women Grow CEO Dr. Chanda Macias at the organization’s 2025 Leadership Summit. Women own majority stakes in approximately 17% of cannabis businesses nationally, per a 2025 Marijuana Business Daily survey. The gap between women as consumers (majority or near-majority in key segments) and women as capital recipients (tiny minority) is one of the most glaring structural contradictions in the legal cannabis industry.

The Menopause and Perimenopause Driver

One of the most underreported stories in cannabis demographics is what is happening in the 45-60 age cohort.

A Canadian study published in Menopause examined 1,485 women aged 35 and over. Among current cannabis users, the most common reasons for use were: sleep difficulties (65%), anxiety (45%), and muscle/joint pain (33%). Over 74% reported that cannabis was helpful for their symptoms. Common formats were edibles (51.7%), oils (47.3%), and smoking (41.1%) — with oral formats dominating in contrast to the general population.

The reason is straightforward. The symptoms most commonly reported in perimenopause and menopause — sleep disruption, hot flashes, mood volatility, joint discomfort, anxiety, and decreased libido — map closely onto the domains where cannabis has the most documented anecdotal relief. And many women in this cohort are specifically seeking non-hormonal options, either due to concerns about traditional hormone replacement therapy or because HRT is contraindicated for them.

Our deeper coverage of this intersection is in the cannabis and menopause piece, which covers what the research actually shows — cautiously, because the clinical evidence is still developing — and what categories of products (low-dose edibles, balanced THC:CBD tinctures, topicals) have the most logical fit with the symptom profile.

The brand landscape is responding. Revelry, founded by Lilach Mazor Power and Stef Swiergol in Arizona, built an entire product line specifically for perimenopause and menopause — day capsules with 2.5mg each of THC, CBD, CBG, and CBN for anxiety and mood; night capsules at a 1:1 THC:CBD ratio (10mg each) for sleep; and a CBD intimacy oil for vaginal dryness. JANE, launched in 2023, built its hemp-derived product line specifically around menopausal and peri-menopausal symptom management.

These are not fringe products for a niche audience. With roughly 6,000 Americans entering menopause every day, the addressable market is substantial and underserved.

The Concentrate Gap

The reversal narrative has an important asterisk: concentrates remain strongly male-dominated, and the gap there has not meaningfully closed.

SAMHSA data shows men are significantly more likely to use inhalable concentrates — waxes, shatters, live resins — while women skew heavily toward oral and topical administration. This is consistent across virtually every data source. The Journal of Cannabis and Cannabinoid Research study of 2,374 cannabis users found men gravitating toward “joints, blunts, vapes, and concentrates” while women preferred “pipes and oral administration methods, such as edibles.”

This matters for two reasons. First, concentrates represent a significant portion of cannabis revenue, particularly in mature legal markets like California, Colorado, and Washington. The concentration of male consumers in this category means the headline “women are catching up” framing needs qualification by format.

Second, concentrates also represent the highest-THC delivery methods — which, given the documented sex differences in THC sensitivity, may explain part of the format preference gap rather than just reflecting cultural tastes. If women are genuinely more sensitive to THC’s psychoactive effects at equivalent doses, high-potency concentrates carry higher risk of the outcomes — anxiety, paranoia, rapid heartbeat — that female consumers consistently report wanting to avoid.

For anyone exploring the evening wind-down ritual or general relaxation use cases, the format question is as important as the strain selection. Low and slow, regardless of your demographic, remains sound advice. Our 100 cannabis tips covers dosing fundamentals that apply across the gender divide.

What This Means for the Industry

The “dude in the dispensary” stereotype — both the customer and the budtender — is becoming a historical artifact faster than most of the industry has acknowledged.

Reuters reported in late 2024 that cannabis retailers are “refocusing shelf space toward products popular with female consumers, including edibles, tinctures, and beverages.” Lauren Carpenter, CEO of Embarc, put it directly: “With women making over 80% of purchasing decisions in the U.S., it’s not just smart, it’s necessary.”

But the retail and product pivots are running ahead of the capital and ownership structures. Women represent close to half or more of cannabis consumers in key segments, but less than 3% of cannabis financing goes to women-owned businesses. The consumption demographic and the ownership demographic are dramatically misaligned — a structural inefficiency that tends to resolve itself eventually, but rarely smoothly.

The education gap is also real. Tatiyana Brooks, co-founder of cannabis data firm GetCannaFacts, notes that “women are more likely to purchase from the industry’s legal market than their male counterparts” — meaning female consumers are already more aligned with legal compliance than the industry sometimes gives them credit for. They are not converting from illegal use to legal use the same way some male-skewing demographics are. They are entering through the legal market, often for the first time, and they need education about product selection, dosing, and terpene effects in a format that does not assume prior cannabis experience.

Your Preferences Are Yours

Here is the part that matters most, and that population-level data tends to obscure.

Group-level trends are real and worth understanding. The research showing women preferring lower doses, oral formats, and linalool-forward profiles is directional and meaningful. But the variance within groups is larger than the variance between groups — meaning there are plenty of women who love high-THC concentrates and plenty of men who prefer 2.5mg microdose gummies. Demographic patterns are starting points for inquiry, not conclusions.

What the data is really telling us is that the cannabis industry has historically been built for one kind of consumer, and the evidence increasingly shows that many consumers — particularly women — were underserved by that design. The corrective happening now is not “cannabis for women” as a patronizing subcategory. It is more accurate formats, more transparent dosing, more varied product formats, and consumption education that starts from wellness rather than recreational excess.

The most honest approach to any cannabis product is tracking what actually works for you — which terpene profiles produce the effects you want, which formats produce predictable results, which THC-to-CBD ratios land in your sweet spot. Population trends can point you toward starting hypotheses. Your own experience over time is the data that matters. That is exactly what the app is built around — logging your own patterns so the signal emerges from your actual experience, not someone else’s demographic average.

---

Sources

• U.S. NIDA / Monitoring the Future panel (2023): women aged 19-30 surpass men in past-year cannabis use
• Amrock GH, Drug and Alcohol Dependence (2026): adolescent gender reversal in cannabis use and CUD, data through 2023
• Compton WM et al., PLOS ONE / PMC (2025): recreational cannabis legalization and gender-differentiated uptake, 2008–2017 NSDUH data
• SAMHSA, National Survey on Drug Use and Health (2022–2023): gender differences in cannabis consumption methods
• YouGov US consumer research (Nov 2024): female cannabis consumer motivations, formats, spending
• New Frontier Data (March 2024): non-flower product preference by gender
• Kaplan JS, Psychoactives (Dec 2024): sex differences in anxiolytic properties of linalool and myrcene
• Reuters (October 2024): young women overtake men in cannabis consumption; retailer strategy shifts
• Herb.co (January 2026): women and cannabis economy analysis with Monitoring the Future citation
• cannabispromotions.com consumer demographics (2025): 42% female share of cannabis consumers, up from 35% in 2020
• THC Annex / SAMHSA (2025): gender differences in marijuana use methods
• PMC — Menopause cannabis study (2023): cannabis use for menopause symptoms in women 35+, Canada
• MG Magazine (March 2026): women in cannabis leadership; 39% executive suite; Statista majority consumer data
• Cannabis Inquirer (March 2026): Black women cannabis entrepreneurs; ownership statistics
• INC. Female Founders 200 (2023): women founders in cannabis
• Veriheal (2024): Revelry cannabis menopause brand